Trial Profile
A multicentre randomized double blind placebo controlled trial of myocardial angiogenesis using VEGF165 intramyocardial gene delivery in patients with severe angina pectoris
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Vascular endothelial growth factor gene therapy (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Acronyms Northern-Trial
- 30 Aug 2006 New trial record.